Today: 21 May 2026
Browse Category

NYSE:PFE 20 November 2025 - 8 December 2025

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer shares traded near $26 on December 8, 2025, with a market cap around $148 billion and a dividend yield of 6.6–7%. The stock remains down about 36% over five years and over 50% below its December 2021 peak. New Phase 3 hemophilia data, an obesity-drug acquisition, and AI-driven cost cuts drew investor attention. Year-to-date total return is flat to slightly positive, depending on dividend inclusion.
8 December 2025
···
Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer shares closed at $26.03 on December 5, 2025, up 1.28% and 24% above April’s low. The stock yields about 6.6% with an annualized dividend of $1.72 per share and has paid 347 consecutive quarterly dividends. Pfizer’s Q3 revenue fell 6% to $16.65 billion, but adjusted EPS beat expectations at $0.87. The stock trades at 8–9x forward earnings, below the market average.
6 December 2025
···
Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer shares traded near $26 late December 5, up about 1%, with a market cap of $146 billion and a dividend yield close to 7%. New analyst coverage flagged tighter FDA COVID vaccine rules and looming patent expirations for key drugs as risks. The stock remains 36% below its five-year level despite recent gains. Investors await updated 2026 guidance and details on a major obesity-drug acquisition.
5 December 2025
···
Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer shares traded at $25.60 late December 3, 2025, near the midpoint of their 52-week range and well below 2021 highs. The stock yields about 6.5–7% and trades at 8–9x forward earnings after a $10 billion obesity-drug deal. Technical analysis points to support near $24.95 and resistance around $26.10. Market capitalization stands near $144 billion.
3 December 2025
···
Pfizer Stock Price Today (PFE): TrumpRx Drug Deal, $10B Metsera Buyout and 2026 Forecast

Pfizer Stock Price Today (PFE): TrumpRx Drug Deal, $10B Metsera Buyout and 2026 Forecast

Pfizer closed at $25.74 on November 28, with a market cap near $146 billion, down about 50% from its 2021–22 COVID peak. Q3 2025 revenue fell 6–7% to $16.7 billion as COVID sales declined, but adjusted EPS beat at $0.87. The company raised 2025 EPS guidance to $3.00–$3.15 and reaffirmed revenue targets. On September 30, Pfizer agreed to cut Medicaid drug prices in exchange for U.S. export tariff relief.
30 November 2025
··
Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer shares closed at $25.74 on November 28, 2025, down 1.8% over the past year. Regulatory filings show new institutional buying, and the company completed a Metsera acquisition worth up to $10 billion. Pfizer reduced its BioNTech stake by 54.7% and raised its full-year EPS guidance to $3.00–$3.15 after reporting $16.7 billion in Q3 revenue.
30 November 2025
····
Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer shares traded near $25.70 late Wednesday morning, down about 0.1%–0.2%. Zacks Research raised its 2025 earnings estimate for Pfizer to $3.15 per share, above Wall Street consensus. Thornburg Investment Management increased its Pfizer stake by 5.7% in Q2, now holding about 10.46 million shares. Pfizer’s next dividend payment is set for December 1.
26 November 2025
·
Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer closed Tuesday at $25.72, up nearly 2%, with a dividend yield of about 6.7% and a market cap near $146 billion. Unusual options activity clustered at the $25 strike followed new FDA approval for PADCEV plus Keytruda in bladder cancer and the completed Metsera obesity drug acquisition. Analyst target averages $28.56. Pfizer trades at a forward P/E of about 8.6, with 2025 total return up 3–4% year-to-date.
26 November 2025
··
PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer shares rose 1.7% to $25.65 by early afternoon Tuesday after the company completed a $10 billion acquisition of obesity-drug developer Metsera. The stock traded between $25.24 and $25.96, with a market cap near $143 billion. Pfizer also reported new FDA approval for PADCEV plus Keytruda in bladder cancer and continued strong options activity at the $25 strike.
25 November 2025
···
Pfizer (PFE) Stock Today: Near‑7% Dividend Yield, Obesity Bet and Pipeline Shift Take Center Stage – November 25, 2025

Pfizer (PFE) Stock Today: Near‑7% Dividend Yield, Obesity Bet and Pipeline Shift Take Center Stage – November 25, 2025

Pfizer shares traded near $25 late Monday, valuing the company at about $143 billion, with a dividend yield of roughly 6.8%. Q3 2025 revenue fell 6% to $16.7 billion, as COVID product sales declined sharply, but non-COVID portfolio sales rose 4%. Adjusted EPS of $0.87 beat expectations by over 30%. Pfizer reaffirmed 2025 revenue guidance and raised its adjusted EPS outlook.
25 November 2025
·
Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer closed Friday at $25.04 per share, with a market cap near $140 billion and a dividend yield close to 7%. The company finalized a multibillion-dollar obesity drug acquisition, won a major U.S. cancer approval, issued $6 billion in bonds, and settled a $41.5 million lawsuit in Texas. Shares remain over 60% below pandemic highs. New analysis highlights both upside and ongoing risks.
23 November 2025
··
Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer closed Friday at $25.04, up 2.6%, with trading volume above 72 million shares. The company completed a $6 billion bond offering late Friday, spanning maturities from 2027 to 2065. Pfizer’s stock is down about 12% over the past year, despite a recent FDA cancer-drug approval and a multi-billion-dollar obesity drug deal. Dividend yield stands near 6.9%.
23 November 2025
···
Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer shares rose 2.62% to close at $25.04 Friday after the FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer and positive data emerged for its mRNA flu vaccine. Volume reached 73 million shares. The stock outperformed Johnson & Johnson and Eli Lilly but remains about 10% below its 52-week high. Pfizer is still down for the year and trades well below pandemic-era peaks.
22 November 2025
··
Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer shares closed up just over 3% at $25.18 on Friday after positive Phase 3 mRNA flu vaccine results, then fell to $24.36 in after-hours trading. The company also completed a $6 billion bond sale to help fund its $10 billion Metsera obesity-drug deal. Pfizer stock remains down about 8% for the year, trailing large-cap pharma peers.
21 November 2025
···
Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Pfizer has closed its $10 billion acquisition of Metsera, paying $65.60 per share plus a contingent value right of up to $20.65 per share. Metsera shares stopped trading on Nasdaq after November 13. On November 21, Pfizer raised $6 billion through a seven-tranche bond sale to help fund the deal. Metsera is now a Pfizer subsidiary.
21 November 2025
···
Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer shares fell 1.7% to about $24.45 on November 20, 2025, with over 44 million shares traded. The stock’s near-7% dividend yield drew attention, but investors weighed legal concerns, new R&D developments, and uncertainty over post-COVID growth. Pfizer’s quarterly EPS dropped 20% year-over-year to $0.62, with a dividend payout ratio near 70%. Management has not indicated plans to cut the dividend.
20 November 2025
···
1 … 5 6 7 8 9 10

Stock Market Today

  • IEA Warns Oil Markets Could Enter 'Red Zone' by July Amid Stock Drawdowns
    May 21, 2026, 8:10 AM EDT. The International Energy Agency (IEA) forecasts oil markets may enter a 'red zone' by July or August due to depleting global stocks and rising demand in the summer travel season. IEA Executive Director Fatih Birol pinpointed the unconditional reopening of the Strait of Hormuz as critical, as this chokepoint handles around 20% of the world's oil and gas shipments. The ongoing Iran conflict and halted shipping there strain supplies, impacting developing Asia and Africa the hardest. Birol noted the recent historic release of 400 million barrels from strategic reserves to offset disruptions, but warned that restoring Middle East production and refining to pre-war levels will take considerable time.

Latest articles

NIO Stock Rises Before Onvo L80 Launch as China EV Demand Faces a Hard Test

Nio slips to red, but margin draws investor attention

21 May 2026
Nio reported first-quarter revenue up 112.2% to RMB25.53 billion ($3.70 billion) and vehicle margin rising to 18.8%. The company posted a net loss of RMB332.1 million, compared to a profit in the previous quarter. Deliveries reached 83,465 vehicles, nearly doubling from a year earlier but down from the fourth quarter. Nio forecast second-quarter revenue and deliveries above analyst expectations.
IBM Stock Tumbles After Earnings Beat as Software Slowdown Reignites AI Fears

IBM, Rigetti, D-Wave gain after $2B quantum investment from Washington

21 May 2026
The Commerce Department will provide $2.013 billion in CHIPS Act incentives to nine quantum computing companies, taking minority, non-controlling equity stakes in each. IBM will receive $1 billion to establish a quantum foundry subsidiary, while GlobalFoundries gets $375 million. Shares of several quantum firms rose sharply in premarket trading following the announcement.
Walmart tops estimates, Wall Street reacts to warning

Walmart tops estimates, Wall Street reacts to warning

21 May 2026
Walmart reported first-quarter net revenue of $177.8 billion, up 7.3%, but shares fell 2% in premarket trading after it forecast weaker-than-expected second-quarter sales and profit. U.S. comparable sales rose 4.1%, and e-commerce jumped 26%. Fuel costs cut operating income by 2.5 percentage points. The company kept its full-year sales and profit outlook unchanged.
Go toTop